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STATE OF THE ART: CONCISE REVIEW
EGFR Inhibitors as First-Line Therapy in Advanced
Non-small Cell Lung Cancer
Thomas Fong, MD,* Daniel Morgensztern, MD,*†‡ and Ramaswamy Govindan, MD*†
Tyrosine kinase inhibitors (TKIs) of the epidermal growth factor
receptor (EGFR), erlotinib and gefitinib, are active agents in the
treatment of advanced non-small cell lung cancer (NSCLC).
Although platinum-based doublet chemotherapy remains the cor-
nerstone for the first-line treatment of metastatic NSCLC, several
phase II and III trials have been conducted utilizing EGFR TKIs
in this setting. Patients with advanced NSCLC who are life long
never-smokers, those with EGFR TK mutations, and those with
bronchioloalveolar cell carcinoma histology seem to have prom-
ising efficacy with first-line therapy with EGFR TKIs compared
with unselected groups of patients receiving the same agents.
Phase III trials have clearly demonstrated no improvement in
survival when EGFR TKIs were combined with conventional
platinum-based doublets, with the exception of subset analysis in
nonsmokers. This review will summarize the results of clinical
trials on erlotinib or gefitinib in the first-line treatment of select
and unselected patients with NSCLC and describe ongoing stud-
ies with these agents in NSCLC.
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Lung cancer is the leading cause of cancer death both in theUnited States1 and worldwide,2 with non-small cell lung
cancer (NSCLC) accounting for approximately 87% of the
newly diagnosed cases.3 The majority of patients present with
unresectable disease, and relapses are common even in those
treated with curative intent.4 The outcomes for patients with
advanced stage is universally poor, with median survival
typically below 10 months in randomized trials with plati-
num-based doublets and patients rarely surviving beyond 2
years.5–7 Despite multiple studies involving different chemo-
therapy combinations, the benefit from systemic cytotoxic
treatment seems to have reached a plateau, where intensifi-
cation of the regimens leads to increased toxicity and no
meaningful improvement in the outcomes.8 Therefore, there
is a great need for the development of novel approaches. One
of the most commonly studied approaches is the targeting of
the epidermal growth factor receptor (EGFR) pathway, which
may be inhibited by either a monoclonal antibody against the
EGFR receptor or by EGFR tyrosine kinase inhibitors (TKIs).
This review will summarize the available data from clinical
trials evaluating the role of EGFR TKIs as the first-line
treatment for NSCLC.
EGFR is a member of the HER/ErbB family of trans-
membrane receptors that forms dimers upon ligand binding,
activating the intracellular TK domain, and triggering down-
stream effector pathways leading to cellular proliferation,
angiogenesis, and metastasis.9 The two classes of agents
targeted at EGFR include monoclonal antibodies directed at
the extracellular domain of the EGFR and low molecular
weight TKIs that inhibit the TK activity of EGFR. Cetuximab
(Erbitux; ImClone, Branchburg, NJ) is a high-affinity anti-
body against the extracellular domain of EGFR that inhibits
tumor growth through EGFR blockade and possibly also
through the induction of immune effector cells. This agent
has an established role in the treatment of colorectal cancer
and head and neck malignancies, but there is little evidence to
support its role in patients with metastatic NSCLC.10 There
are two low molecular weight EGFR TKIs currently used in
the treatment of advanced NSCLC. Gefitinib (Iressa; Astra-
Zeneca, Wilmington, DE) was the first agent of this class
approved by the U.S. Food and Drug Administration (FDA)
in May 2003 for third-line therapy in NSCLC,11 but is
currently no longer available in the United States outside of
clinical trials. Erlotinib (Tarceva; Genentech, San Francisco,
CA) was approved by the FDA in November 2004 for
advanced NSCLC that had progressed through at least one
prior chemotherapy regimen.12
Given the efficacy of EGFR TKIs in advanced NSCLC
in the salvage setting, along with their favorable toxicity
profile compared with conventional chemotherapy, there is
considerable interest in evaluating their efficacy in the first-
line treatment for NSCLC.
Overview of EGFR Agents in Advanced NSCLC
Clinical efficacy of EGFR TKIs in advanced NSCLC
has been observed in several trials. In BR.21, the Canadian
phase III trial that led to FDA approval for erlotinib, 731
patients with NSCLC previously treated with one or two
chemotherapy regimens were randomized to receive erlotinib
or placebo.13 Erlotinib was shown to be superior to placebo in
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terms of response rates (RRs) (9% to 1%), progression-free
survival (PFS) (2.2 months versus 1.8 months), and overall
survival (OS) (6.7 months versus 4.7 months, all p-values
0.001). Gefitinib was noted to have clinically meaningful
antitumor activity in the multinational IDEAL-1 trial. In this
phase II study of 210 patients with advanced NSCLC, ge-
fitinib led to objective response in 19% and median survival
of 8 months.14 Disappointingly, however, gefitinib was not
superior to best supportive care in previously treated NSCLC
patients in the placebo-controlled, phase III Iressa Survival
Evaluation in Lung Cancer (ISEL) trial.15 In this study of
1692 patients randomized in a 2:1 fashion to receive gefitinib
or placebo, median survival was 5.6 months and 5.1 months,
respectively (p  0.08). Although gefitinib failed to improve
survival in patients with previously treated NSCLC and is no
longer prescribed in the United States,15 this agent continues
to be used in several other countries.
Subset analyses from multiple studies involving EGFR
TKIs identified subgroups of patients with clinical and mo-
lecular features associated with increased probability of ben-
efit to this therapy. In the BR.21 trial,13 erlotinib responses
were significantly more common in never-smokers than ever
smokers, women than men, Asians than other races, and
adenocarcinoma versus other histologies. Furthermore, de-
spite the negative overall results in the ISEL study of ge-
fitinib,15 preplanned subgroup analysis showed significantly
longer survival in never-smokers and in Asians. In addition to
adenocarcinoma histology, bronchioloalveolar cell carcinoma
(BAC) has been described to be particularly sensitive to
gefitinib.16 Skin rash also correlates with increased likelihood
of response to EGFR TKIs in NSCLC.17 Still, despite differ-
ing response rates observed in certain patient subgroups, no
clear survival advantage in regards to patient characteristics
could be demonstrated in these trials. The prognostic impor-
tance of these features is still under discussion, and clinical
response may be seen outside these well-known subgroups.
The EGFR monoclonal antibody cetuximab has been
evaluated in patients with advanced NSCLC to a limited
extent. In a randomized phase II trial of first-line cisplatin/
vinorelbine with or without cetuximab, higher response rates
(35% and 28%, respectively) and improved PFS (4.8 months
and 4.2 months) favored addition of cetuximab to chemother-
apy.18 A phase II trial conducted by the Southwest Oncology
Group (SWOG) randomized previously untreated patients
with advanced NSCLC to receive carboplatin/paclitaxel with
concurrent cetuximab followed by maintenance cetuximab,
or the same chemotherapy with sequential cetuximab.19 Of
the 195 evaluable patients, similar response rates (34% and
31%, respectively), PFS (4 months, both arms), and OS (11
and 10 months, respectively) were observed. A randomized
phase II trial of gemcitabine/platinum with or without cetux-
imab as first-line treatment for advanced NSCLC was re-
cently reported.20 Trends suggesting benefit were observed
with higher response rates (28% versus 18%), PFS (5.1
month versus 4.2 months), and OS (12.0 months versus 9.3
months) in the cetuximab arm. A randomized multicenter
phase III study of first-line taxane/carboplatin with or without
cetuximab enrolled 676 advanced NSCLC patients at 97 U.S.
centers.21 There was no difference in the primary end point of
PFS (hazard ratio 0.90, 95% confidence interval, 0.76–1.07),
though response rates were higher in the cetuximab arm (26%
versus 17%). The phase III multinational First-Line Treat-
ment for Patients with EGFR-Expressing Advanced NSCLC
(FLEX) trial randomized over a thousand patients to receive
cisplatin/vinorelbine with or without cetuximab.22 Although
details have not yet been published, the study was positive for
its primary end point of OS according to recent press release.
Until the FLEX trial, results with first-line chemotherapy and
the EGFR monoclonal antibody cetuximab have been mod-
est, and the rest of this review will focus on first-line EGFR
TKIs alone or in combination with chemotherapy in select
and unselected patients with advanced NSCLC.
Molecular Predictors of Response to EGFR TKI
Therapy
One of the molecular predictors associated with re-
sponse to TKIs in NSCLC is the presence of specific activat-
ing EGFR mutations. Lynch et al. reported the presence of
EGFR mutations in eight of nine patients treated with ge-
fitinib who were known to have clinical response, whereas
none of seven patients who failed to respond to gefitinib had
mutations.23 All detected mutations were small in-frame de-
letions or amino acid substitutions clustered within the TK
domain of EGFR. In a similar study of patients with NSCLC,
EGFR TK mutations were found in 15 of 58 tumor samples
from Japan and 1 of 16 from the United States.24 Mutations
were correlated with known clinical predictors of response to
EGFR TKIs, as they were detected more commonly in
women, Japanese, and patients with adenocarcinoma. High
EGFR gene copy number may be identified by fluorescence
in situ hybridization (FISH) analysis in approximately 25% to
35% of NSCLC patients.25 In a correlative study to ISEL,
FISH-positivity was predictive of a survival benefit from
gefitinib.26 FISH-positive patients also had improved survival
with erlotinib in univariate analysis in the BR.21 trial.27
Nevertheless, in multivariate analysis, neither EGFR expres-
sion by immunohistochemistry, high EGFR copy number by
FISH, or EGFR mutation status were significantly predictive
for survival after treatment with erlotinib. In the INVITE
study of previously untreated elderly patients with advanced
NSCLC, FISH-positive patients had improved survival when
treated with gefitinib compared with vinorelbine (hazard ratio
2.88, 95% confidence interval, 1.21, 6.83).28 In the INTEREST
trial of gefitinib versus docetaxel in previously treated
NSCLC patients, though, EGFR FISH status had no impact
on survival.29 EGFR expression detected by immunohisto-
chemistry was also found to correlate with response to erlo-
tinib and survival in subset analysis of the BR.21 trial, though
the survival benefit did not persist in multivariate analysis.27
K-ras mutations, frequently detected in heavy smokers, have
been found to be associated with resistance to EGFR TKIs in
NSCLC. Mutations in K-ras exon 2 (amino acid substitutions
in codons 12 or 13 in each case) were found in 24% of
refractory tumors, but in none of the tumors sensitive to
EGFR TKIs (p  0.02) in one study.30 K-ras mutations seem
to be strong predictors for lack of response to EGFR TKIs.
Fong et al. Journal of Thoracic Oncology • Volume 3, Number 3, March 2008
Copyright © 2008 by the International Association for the Study of Lung Cancer304
First-Line EGFR TKI Therapy in Clinical Trials in
Select Populations
Never-smokers
In a phase II trial, gefitinib 250 mg daily was given as
initial therapy for 54 patients with advanced NSCLC, all
never-smokers with adenocarcinoma histology.31 All but four
patients enrolled in this Korean study were female. The
overall response rate was 61% with median PFS of 26 weeks
(6 months) and 1-year survival of 79%. The median duration
of response in the 33 responders was 30 weeks (7 months).
Although it is difficult to interpret an uncontrolled small
phase II study, the response rates and 1-year survival are far
better than what is commonly reported with platinum-based
doublet therapy (Table 1).
First-line gefitinib was also given in a prospective
multicenter phase II trial (ONCOBELL) of advanced NSCLC
patients who were EGFR FISH-positive, phospho-Akt posi-
tive and/or never-smokers.32 The rationale for the molecular
selection criteria was previous work by the authors suggest-
ing increased sensitivity to EGFR TKIs in patients positive
both for EGFR by FISH and for the antiapoptotic protein
phospho-Akt.33 Both chemotherapy-naive and previously
treated patients were included in this study, and gefitinib was
the first-line therapy in 16 of the 42 patients (38%). Overall
response was 48%, with a RR of 50% in untreated and 46%
in previously treated patients. The median time to disease
progression was 6.4 months, and 1-year survival was 64%.
Both of these phase II studies suggest promising efficacy of
first-line EGFR TKI monotherapy in never-smokers.
Subset analyses from two large randomized, placebo-
controlled, phase III trials also suggest that never-smokers
with advanced NSCLC may derive benefit from first-line
EGFR TKIs in combination with chemotherapy.34,35 In
TRIBUTE,34 never-smokers treated with erlotinib combined
with chemotherapy had significantly better survival than
those receiving chemotherapy alone, 22.5 months versus 10.1
months. These patients also had superior time to progression
(TTP) and objective RR (Table 1). In the Tarceva Lung
Cancer Investigation Trial,35 erlotinib was also superior in
never-smokers in terms of PFS (7.9 months versus 5.4
months, p  0.02) and median survival (not reached versus
11.4 months) (Table 1). These results suggest the possible
role of EGFR TKIs alone or in combination with conven-
tional chemotherapy in the first-line treatment of NSCLC in
never-smokers. There is an ongoing phase II study designed
to confirm the benefit of erlotinib with or without chemother-
apy in never-smokers in the first-line setting (CALGB
30406). Of note, clinical characteristics such as female gen-
TABLE 1. Trials of First-Line EGFR TKIs in Selected Patients with NSCLC










Lee31 G 55 61 6.5 mo NR 79
Cappuzzo32 (ONCOBELL) G 42 48 6.4 mo NR 64
Herbst34 (TRIBUTE subset) E  CbP 72 30 6.0 mo 22.5 mo NR
Gatzemeier35 (TALENT subset) E  CsGem 8 NR 7.9 mo NR NR
EGFR-selected
Asahina38 G 16 75 8.9 mo NR 88
Cappuzzo32 (ONCOBELL) G 42 48 6.4 mo NR 64
Paz-Ares39 E 21 90 NR NR NR
Sequist40 (iTARGET) G 31 55 11.4 mo 20.8 mo NR
BAC
Miller50 E 33 27 NR NR NR
West51 G 101 17 4 mo 13 mo 51
Bearz52 E or G 16 44 NR NR NR
Cadranel53 G 88 13 2.5 mo NR NR
Elderly
Jackman42 E 80 10 3.5 mo 10.9 mo 46
Swinson45 G 41 10 1 mo 2.7 mo NR
Crino28 (INVITE) G 97 3 NR NR NR
V 99 5 NR NR NR
Poor PS
Lilenbaum46 E 46 2 2.5 mo NR NR
CbP 42 10 4.0 mo NR NR
Hesketh47 E 72 8 2.1 mo 5.0 mo 22
Spigel48 G 70 4 3.7 mo 6.3 mo 24
G, gefitinib; E, erlotinib; Cb, carboplatin; P, paclitaxel; Cs, cisplatin; Gem, gemcitabine; V, vinorelbine; RR, response rate;
TTP, time to progression; PFS, progression-free survival; MST, median survival time; NR, not reported; pts, patients; mo,
months.
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der, Asian ethnicity, and adenocarcinoma histology were not
predictors for benefit from erlotinib or gefitinib in any of the
four phase III, randomized trials assessing EGFR TKIs in
combination with chemotherapy as first-line treatment of
advanced NSCLC.34–37
EGFR TK Mutations
NSCLC patients with EGFR TK mutations were treated
with first-line gefitinib in a phase II study conducted in
northeastern Japan.38 In this trial, 82 patients were screened
for known activating EGFR TK mutations in exons 18–21,
which were found in 20 patients (24%). Genomic DNA was
isolated from tumor specimens, sequenced, and detected
mutations confirmed by PCR amplification and repeat se-
quencing. Sixteen patients, predominantly female and never-
smokers, were enrolled and treated with gefitinib. Objective
response was seen in 75%, and all but two patients were alive
at 1 year (88%). In a Spanish trial of erlotinib for previously
untreated patients with advanced NSCLC with EGFR TK
mutations, 37 of 297 tumors screened were found to have
mutations.39 Preliminary data shows that for 21 evaluable
patients, response was observed in 90% (6 CR, 13 PR). A
U.S. trial of first-line gefitinib in patients with advanced
NSCLC and EGFR mutations, iTARGET, found mutations in
34 of the 98 patients screened.40 Gefinitib was given to 31
patients, with response observed in 55%, PFS of 11 months,
and OS of 21 months (Table 1). Although these are small and
limited studies, these results compare favorably to conven-
tional chemotherapy in this select patient group. A phase III
trial is currently being conducted by the Spanish Lung Cancer
Group in which previously untreated patients with EGFR TK
mutations are being randomized to receive erlotinib or four
cycles of platinum-based chemotherapy, with PFS as the
primary end point.41 This study will likely further clarify the
role of EGFR TKIs in the first-line treatment of patients with
advanced NSCLC and mutations in the TK domain of EGFR.
Elderly Patients
Elderly patients have also been evaluated for first-line
EGFR TKI therapy given the concern for treatment-related
toxicities with conventional chemotherapy (Table 1). In a
phase II study of patients aged 70 or older with advanced
NSCLC and no prior chemotherapy, 80 patients were treated
with erlotinib monotherapy.42 Partial response was seen in
10%, and an additional 41% achieved stable disease for at
least 2 months. The median survival, 1-year survival, and
2-year survival were 11 months, 46%, and 19%, respectively.
These are favorable results when compared with trials eval-
uating first-line chemotherapy in elderly patients with ad-
vanced NSCLC.43,44 Crino et al. recently reported on gefitinib
versus vinorelbine in previously untreated elderly patients
with advanced NSCLC in the randomized phase II INVITE
trial.28 Although the primary end point of superior PFS for
gefitinib was not met in this trial of 196 patients, gefitinib was
similar to vinorelbine in terms of PFS, RR, and OS, and was
better tolerated and associated with higher quality of life
improvement compared with vinorelbine. In another phase II
trial of patients over 70 years of age with advanced NSCLC
unfit or unwilling for chemotherapy, gefitinib was given as
first-line therapy with predictably modest results.45 Of 41
evaluable patients, 10% achieved PR. Nevertheless, PFS was
only 32 days, with median survival of 82 days. Despite these
results, it is fair to state that elderly patients (not otherwise
selected by EGFR TK mutations or smoking status) seem to
tolerate EGFR TK inhibitors reasonably well. Even though
the primary end point was not met, the results from the
INVITE study suggest at least in certain elderly patients that
EGFR TK inhibitors may produce outcomes similar to single
agent chemotherapy. This issue needs to be studied further in
prospective trials.
Performance Status
First-line EGFR TKI therapy has been evaluated in
advanced NSCLC patients with poor performance status
(PS). In a randomized phase II trial, erlotinib monotherapy
was compared with conventional platinum-based doublet
chemotherapy (carboplatin and paclitaxel) in patients with
advanced NSCLC and PS of 2. In preliminary results, RR
(10% versus 2%) and PFS (4.0 months versus 2.5 months) are
significantly better with chemotherapy than erlotinib.46 Erlo-
tinib as first-line therapy for patients with advanced NSCLC
and PS of 2 was also given in a SWOG phase II trial
(S0341).47 In a preliminary report of 72 evaluable patients,
8% had response and median OS was 5 months. In a phase II
nonrandomized trial, gefitinib monotherapy was given as
first-line therapy in patients with advanced NSCLC and PS 2
or 3. Of 70 patients, partial response was seen in 4%, with
median OS of 6.3 months.48 These data do not support the use
of EGFR TKIs in the first-line setting solely based on PS
alone. An ongoing phase III trial in the United Kingdom
(TOPICAL) in patients with PS 2 or 3 or with renal insuffi-
ciency will likely provide further insight regarding the use of
EGFR TKIs in this patient population.41
BAC
Patients with BAC, a histologic subtype of adenocar-
cinoma, have been shown to be particularly responsive to
EGFR TKIs in phase II trials. Although the pathophysiology
is not clear at this time, the postulated mechanisms include
the possibility of more common EGFR mutations and EGFR
amplification in patients with pure BAC, BAC with focal inva-
sion, or adenocarcinoma with BAC features.49 In a retrospective
review of 139 patients treated with gefitinib at Memorial Sloan-
Kettering Cancer Center, higher response rates were noted in
adenocarcinoma versus other NSCLC (19% versus 0%).16 Ad-
ditionally, adenocarcinoma with BAC features or pure BACwas
associated with higher response compared with other adenocar-
cinomas (38% versus 14%, p  0.001). When tested in multi-
variate analysis, bronchioloalveolar features remained signifi-
cant as an independent predictor of response.
In a phase II trial of erlotinib for first-line treatment in
unselected patients with advanced NSCLC, BAC was found
to be associated with longer OS in subset analysis.17 Six
patients with BAC had a median survival longer than 607
days, a statistically significant increase compared with ade-
nocarcinoma, squamous, or other histology. A prospective
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phase II trial of 33 patients with BAC (adenocarcinoma with
BAC features, pure BAC or BAC with focal invasion) re-
ported a 27% objective response to first-line therapy with
erlotinib.50 In the SWOG phase II trial S0126, 136 patients
(101 chemotherapy-naive) with advanced BAC were treated
with gefitinib, leading to objective responses in 17% and
median survival of 13 months.51 Subset analysis revealed
improved survival in women, never-smokers, patients with
good PS, and patients who developed a rash. In another trial
of 16 patients with BAC,52 in which all patients were Cau-
casian, female, and never-smokers, first-line erlotinib or ge-
fitinib resulted in objective response in 44%. This report also
noted the interesting finding that all responders had normal
CA 15-3 levels before treatment, whereas all nonresponders
had abnormal CA 15-3 levels. A French phase II study
administered gefitinib as first-line treatment in advanced
adenocarcinoma with BAC features,53 with partial responses
noted in 13% and median PFS of 3 months. Phase III trials of
EGFR TKIs in this limited patient subgroup have not been
conducted. Nevertheless, based on the available evidence,
patients with BAC may be reasonable candidates for first-line
therapy with EGFR TKIs.
First-Line EGFR TKI Therapy in Clinical Trials:
Unselected Patients
Single-agent
Given the plateau in benefits achieved with platinum-
based doublet chemotherapy, the toxicities associated with
these regimens, and the promising results with EGFR TKIs in
the salvage setting, there has been understandable enthusiasm
in evaluating EGFR TKIs for first-line therapy in all patients
with advanced NSCLC (Table 2). In a phase II trial of 53
chemotherapy-naive patients receiving erlotinib for the treat-
ment of advanced NSCLC, objective response was seen in
23%, median TTP was 84 days, and median OS was 391
days.17 Patients were not selected by any known clinical
predictors in this study, and treatment was well-tolerated.
Results were more modest in a phase II trial of first-line
gefitinib in unselected patients with advanced NSCLC.54 Of
58 evaluable patients in this multicenter study, objective
response was observed in 5%, and stable disease in an
additional 40%. Median PFS was 7 weeks, and median
survival was 29 weeks. In an earlier prospective phase II trial
of chemotherapy-naive patients with advanced NSCLC, 40
patients treated with first-line gefitinib were evaluated for
response.55 PR was seen in 12 (30%) patients. Nevertheless,
4 (10%) patients died of interstitial lung disease. The authors
acknowledged that this severe toxicity was not acceptable for
first-line therapy. This incidence of death from interstitial
lung disease has not been observed in other trials with
gefitinib, perhaps due in part from greater investigator aware-
ness of this potential toxicity and earlier discontinuation of
therapy when appropriate. Further, this latter trial was con-
ducted in an Asian population, whereas the former two trials
described were conducted in a Caucasian population, likely
contributing to differences in the response rates and toxicities.
The recently reported phase III INTEREST29 trial confirmed the
efficacy of EGFR TKIs in the salvage setting, as gefitinib
monotherapy led to noninferior survival, along with more favor-
able toxicity profile and superior quality of life measurements
when compared with docetaxel. There have been no published
randomized phase III trials utilizing first-line erlotinib or ge-
fitinib monotherapy to date, though first-line erlotinib mono-
therapy is a treatment arm in the TOPICAL and TORCH trials
that are currently accruing patients (Table 3).
Combination with Chemotherapy
The combination of EGFR TKIs with first-line chemo-
therapy for advanced NSCLC has failed to show benefit
compared with chemotherapy alone in four large randomized,
phase III trials.34–37 In the TRIBUTE trial of over 1000
patients, those treated with erlotinib in combination with
carboplatin and paclitaxel fared no better than placebo in
terms of RR, TTP, or OS.34 Patients in this trial were not
selected based on known prognostic factors. Whereas the
subgroup of never-smokers had improved outcomes, erlotinib
TABLE 2. Trials of First-Line EGFR TKIs in Unselected Patients with NSCLC










Giaccone17 E 53 23 3 mo 13 mo 54
Reck54 G 58 5 1.7 mo 6.7 mo NR
Niho55 G 40 30 NR 13.9 mo 55
Phase III
Herbst34 (TRIBUTE) E  CbP 526 22 5.1 mo 10.6 mo 22
CbP 533 19 4.9 mo 10.5 mo 19
Gatzemeier35 (TALENT) E  CsGem 580 32 7.9 mo 10.0 mo 41
CsGem 579 30 5.4 mo 10.2 mo 42
Giaccone36 (INTACT-1) G  CsGem 730 51 5.7 mo 9.9 mo 42
CsGem 365 47 6.0 mo 10.9 mo 44
Herbst37 (INTACT-2) G  CbP 692 30 5.0 mo 9.3 mo 39
CbP 345 29 5.0 mo 9.9 mo 42
E, erlotinib; G, gefitinib; Cb, carboplatin; P, paclitaxel; Cs, cisplatin; Gem, gemcitabine; RR, response rate; TTP, time to
progression; PFS, progression-free survival; MST, median survival time; NR, not reported; pts, patients; mo, months.
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with concurrent chemotherapy did not confer a survival
advantage over chemotherapy alone in the overall patient
population. In the Tarceva Lung Cancer Investigation Trial
(TALENT), 1172 patients received either erlotinib or placebo
in combination with up to six cycles of cisplatin and gemic-
itabine, followed by maintenance erlotinib or placebo.35 This
was also performed in unselected patients with advanced
NSCLC, and likewise failed to demonstrate benefit for erlo-
tinib in the specified primary end point of OS or secondary
endpoints of RR, TTP, duration of response, or quality of life.
Gefitinib in combination with chemotherapy was like-
wise not shown to have improved efficacy over chemotherapy
alone in unselected patients with advanced NSCLC in phase
III trials. This was evaluated in two trials of identical design
using different chemotherapy regimens. The Iressa NSCLC
Trial Assessing Combination Treatment (INTACT) 1 (enroll-
ing mostly European patients) used cisplatin and gemcitab-
ine, whereas INTACT 2 (predominantly American patients)
used the combination of carboplatin and paclitaxel.36,37 In
both of these trials, chemotherapy was combined with one of
three treatment arms: placebo, gefitinib 250 mg/d, or gefitinib
500 mg/d. Over 1000 previously untreated patients were
recruited for each of these trials, with primary end points
including OS, TTP, RR, and safety evaluations. Median
survival times for gefitinib 500 mg/d, gefitinib 250 mg/d, and
placebo were 9.9, 9.9, and 10.9 months, respectively, in
INTACT 1, and 8.7, 9.8, and 9.9 months, respectively, in
INTACT 2. No difference in any of the efficacy end points
between the treatment groups was observed in either of these
trials. Proposed reasons for lack of efficacy in these phase III
trials include mechanistic interactions between chemotherapy
and EGFR TKIs. The effects of EGFR TKIs in regards to
antiproliferation and cell-cycle arrest were speculated to pos-
sibly render tumor cells less sensitive to cytotoxic agents.35
Based on the results of the above trials, EGFR TKIs as
monotherapy or in combination with conventional chemo-
therapy cannot be recommended as first-line therapy in uns-
elected patients with advanced NSCLC.
Comparison with Standard Chemotherapy
Although the response rates from single-agent EGFR
TKIs in the first-line setting of unselected patients are typi-
cally lower than combination chemotherapy, disease-free
survival is comparable, particularly in elderly patients treated
with single agent. The efficacy of first-line EGFR TKIs in




Erlotinib vs. platinum-based chemotherapy New Mexico (US)
Phase II—select patients
EGFR Status
Gefitinib Korea EGFR mutations
Erlotinib with or without carboplatin/paclitaxel Multicenter (US) EGFR overexpression and/or EGFR amplification
Never-smokers
Erlotinib with or without carboplatin/paclitaxel Multicenter (US) Never-smokers and adenocarcinoma
Adenocarcinoma
Erlotinib Multicenter (US) Adenocarcinoma and women
Elderly (70 yr)
Erlotinib and/or gemcitabine NCI (US)
Erlotinib/pemetrexed/bevacizumab Moffitt (US)
Performance status
Erlotinib Multicenter (US) PS 0–1 and less than 10% weight loss
Erlotinib/bevacizumab Multicenter (US) PS 2
Gefitinib vs. carboplatin/gemcitabine Multicenter (Canada) PS 2
Phase III—unselected patients
Erlotinib, then 2nd line cisplatin/gemcitabine vs. Multicenter
Cisplatin/gemcitabine, then 2nd line erlotinib (TORCH) (Italy, Canada)
Phase III—select patients
EGFR Status
Erlotinib vs. chemotherapy Multicenter (Spain) EGFR mutations
Never smokers
Gefitinib vs. cisplatin/gemcitabine Multicenter (Korea) Never-smokers and adenocarcinoma
Gefitinib vs. carboplatin/paclitaxel Multicenter (Asia)
Unsuitable for chemotherapy
Erlotinib vs. placebo (TOPICAL) United Kingdom PS 2–3 or renal insufficiency
NCI, National Cancer Institute.
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comparison with standard chemotherapy is being investigated
in a number of ongoing trials (Table 3).41
Comments
Despite the negative overall findings of four random-
ized, phase III trials evaluating first-line EGFR TKIs with
chemotherapy in unselected patients with advanced NSCLC,
there is strong evidence that certain subsets of patients may
be appropriate candidates for first-line EGFR-targeted thera-
pies. In particular, never-smokers seem to have promising
overall and PFS benefit from first-line EGFR TKI therapy
alone or in combination with chemotherapy. Impressive re-
sults have been observed in EGFR TKI first-line therapy in
the never-smoker population in phase II and subset analyses
of phase III studies. Patients with EGFR TK mutations have
been shown to have significant response to EGFR TKIs;
however, these mutations are present only in a small percent-
age of patients in the Western hemisphere. Finally, patients
with BAC histology have been shown to have promising
efficacy with first-line EGFR TKI therapy in small studies.
Patients with NSCLC who are never-smokers and those who
have EGFR mutations and/or BAC histology seem to respond
to first-line single-agent EGFR TKIs with results comparable
to conventional chemotherapy. Nevertheless, whether these
clinical or molecular features are valid prognostic or predic-
tive markers can only be definitively ascertained through
prospective randomized phase III studies. Until then, the use
of erlotinib or gefitinib as first-line therapy for advanced
NSCLC remains investigational.
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